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Head and neck cancer
FDG-PET
Radiomicsa b s t r a c t
Background and purpose: Current prediction of radiation-induced xerostomia 12 months after radiother-
apy (Xer12m) is based on mean parotid gland dose and baseline xerostomia (Xerbaseline) scores. The
hypothesis of this study was that prediction of Xer12m is improved with patient-specific characteristics
extracted from 18F-FDG PET images, quantified in PET image biomarkers (PET-IBMs).
Patients and methods: Intensity and textural PET-IBMs of the parotid gland were collected from pre-
treatment 18F-FDG PET images of 161 head and neck cancer patients. Patient-rated toxicity was prospec-
tively collected. Multivariable logistic regression models resulting from step-wise forward selection and
Lasso regularisation were internally validated by bootstrapping. The reference model with parotid gland
dose and Xerbaseline was compared with the resulting PET-IBM models.
Results: High values of the intensity PET-IBM (90th percentile (P90)) and textural PET-IBM (Long Run
High Grey-level Emphasis 3 (LRHG3E)) were significantly associated with lower risk of Xer12m. Both
PET-IBMs significantly added in the prediction of Xer12m to the reference model. The AUC increased from
0.73 (0.65–0.81) (reference model) to 0.77 (0.70–0.84) (P90) and 0.77 (0.69–0.84) (LRHG3E).
Conclusion: Prediction of Xer12m was significantly improved with pre-treatment PET-IBMs, indicating
that high metabolic parotid gland activity is associated with lower risk of developing late xerostomia.
This study highlights the potential of incorporating patient-specific PET-derived functional characteris-
tics into NTCP model development.
 2017 The Author(s). Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 126 (2018) 89–95
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).18F-FDG PET imaging provides functional information about the
metabolic activity of tissue. This makes 18F-FDG PET a powerful
and widely used diagnostic modality in oncology. In head and neck
oncology, 18F-FDG PET can complement other image modalities in
tumour staging and delineation for radiotherapy [1,2]. The com-
mon clinical use of 18F-FDG PET allows for the possibility to extract
large amounts of patient-specific functional information that could
contribute to prognosis for head and neck cancer (HNC) patients.
Several studies have shown that PET image characteristics of the
tumour can contribute to predicting overall, disease-free or
event-free survival [3–6]. However, patient-specific image charac-
teristics for predicting normal tissue radiation toxicities are less
explored, while these are also crucial in supporting treatment deci-
sions. Additionally, new radiation techniques (e.g. proton therapy
[7] and magnetic resonance imaging (MRI) guided radiation [8])may allow for better sparing of normal tissue. These new tech-
niques demand improved prediction models, to select patients
most at risk of developing toxicities [9].
Radiation-induced xerostomia is a major and frequent side
effect for HNC patients, and has a considerable impact on these
patients’ quality of life [10]. Conventional Normal Tissue Complica-
tion Probability (NTCP) models that predict patient-rated xerosto-
mia are based on dose–volume parameters and baseline
complaints [11,12]. However, there is still a significant, unex-
plained variance in predicting xerostomia with these models.
Therefore, the demand persists to improve the identification of
patients at risk. Previous work showed that patient-specific CT
characteristics of the parotid glands could significantly improve
the prediction of patient-rated xerostomia, however, model perfor-
mance improvement was marginal [13]. The hypothesis was that
the predictive CT characteristic is related to the ratio of non-
function to functional parotid tissue. It can be expected that this
ratio would be better represented by image characteristics from
functional imaging (i.e. PET or MR images).
90 18F-FDG-PET-image biomarkers improve xerostomia predictionIn this study, the relationship was tested between metabolic
activity of the parotid gland and late xerostomia. Consequently,
the patient-specific response to radiation in developing this
toxicity was investigated. The purpose was to determine whether
functional information from 18F-FDG PET images, which is quanti-
fied in PET-image biomarkers (PET-IBMs), was associated with
patient-rated moderate-to-severe xerostomia 12 months after
radiotherapy (Xer12m). Since current NTCP prediction models are
based on parotid gland dose and baseline complaints, the study
subsequently addressed whether PET-IBMs could improve on the
current prediction of Xer12m
Materials and methods
Patient demographics and treatment
18F-FDG PET/CT scans were acquired of 161 HNC patients in
treatment position before the start of radiotherapy. The patients
were treated with definitive radiotherapy either with or without
concurrent chemotherapy or cetuximab, between November
2010 and August 2015. Patients without follow-up data 12 months
after radiotherapy were excluded from this study. Patients were
also excluded if they underwent surgery in the head and neck area
before or within one year after treatment.
A detailed description of the radiotherapy protocols is given in
previous studies [13,14]. In summary, all patients were treated
with IMRT or VMAT using a simultaneous integrated boost (SIB)
technique. The parotid glands and the swallowing structures were
spared as much as possible without compromising the dose to the
target volumes [14,15]. Patients received a total dose of 70 Gy
(2 Gy per fraction, 5 or 6 times a week) to the primary tumour
and, if present, pathological lymph nodes. A radiation dose of
54.25 Gy (1.55 Gy per fraction, 5 or 6 times a week) was delivered
to the elective lymph node levels.Endpoints
The primary endpoint was patient-rated moderate-to-severe
xerostomia 12 months after radiotherapy (Xer12m), which corre-
sponds to the 2 highest scores of the 4-point Likert scale of the
EORTC QLQ-H&N35 questionnaire. This endpoint was prospec-
tively assessed as part of a Standard Follow-up Program (SFP) for
Head and Neck Cancer Patients (NCT02435576), as described in
previous studies [11,12,16].Dose and clinical parameters
For treatment planning, parotid glands were delineated on the
planning (PET/)CT scans. The mean dose to both the contra- and
ipsilateral parotid and submandibular glands were extracted from
the dose–volume information [11,17]. In addition, baseline
patient-rated xerostomia (Xerbaseline) was also considered (none
vs. any).
Patient characteristics such as age, sex, WHO-performance,
tumour stage and body mass index did not significantly add to
the parotid gland dose and Xerbaseline in predicting Xer12m in previ-
ous studies [11,13,18]. This was again observed in the current
cohort, therefore these variables were not further reported in this
study.18F-FDG PET acquisition
Approximately 2 weeks before the start of radiotherapy,
18F-FDG PET/CT images (Siemens Biograph 64-slice PET/CT scan-
ner, Siemens Medical Systems, Knoxville, TN, USA) were acquired
in with the patient positioned for radiotherapy. PET/CT systemperformance were initially harmonised conform the Netherlands
protocol for FDG PET imaging [19] and later by EARL accreditation
[20].
Patients were instructed not to eat or drink 6 h before scanning,
but were encouraged to drink water to ensure adequate hydration.
A body weight-based intravenous injection dose of 3 MBq/kg was
administered 60 min prior to the 18F-FDG PET acquisition.
18F-FDG PET images were acquired in the caudal–cranial direction
with an acquisition time of 3 min per bed position.Candidate PET-image biomarkers
Intensity PET-IBMs were extracted, representing first order
standardised uptake value (SUV) characteristics of the delineated
contra-lateral parotid glands. Examples are mean, minimum, max-
imum, standard deviation and root mean square of the SUVs. For
the complete list of the 24 intensity PET-IBMs, see Supplementary
data 1. Fig. 1 shows a schematic representation of PET-IBMs’
extraction process.
Furthermore, more complex, textural features were extracted
describing the intensity heterogeneity. These textural PET-IBMs
were extracted from the grey level co-occurrence matrix (GLCM)
[21], grey level run-length matrix (GLRLM) [22,23], grey level
size-zone matrix (GLSZM) [24] and neighbourhood grey tone dif-
ference matrix (NGTDM) [25]. GLCM describes the grey level tran-
sitions. GLRLM and GLSZM describe the directional and volumetric
grey level repetitions, respectively. NGTDM describes the relation-
ship of sum and averages of grey level differences of direct adjacent
voxels.
For this study, the average of PET-IBMs from GLCM and GLRLM
in 13 independent directions was used. The range of SUVs was
binned with a fixed bin size of 0.25. Discretisation of SUV is neces-
sary to reduce the number of possible intensity values, and so
reduce noise when calculating textural features [26]. All 66 textu-
ral PET-IBMs (25 GLCM, 18 GLRLM, 18 GLSZM and 5 NGTDM) were
normalised by subtracting the average from the PET-IBMs’ values
and then dividing by the standard deviation. For the complete list
refer to Supplementary data 2. All PET-IBMs were extracted in
MATLAB (version R2014a).Univariable analysis
Univariable logistic regression analysis was performed to
evaluate the basic associations of PET-IBMs with late xerostomia.
p-Values <0.05 were considered statistically significant. Coeffi-
cients (b) were evaluated to understand the effect that is described
by the PET-IBMs in relation to Xer12m. The univariable analysis was
not used for the variable selection.Multivariable analysis
Reference model
A reference prediction model was evaluated for the current
patient cohort. This model was based on the mean dose to the con-
tralateral parotid gland and Xerbaseline. These were the predictors
that were identified by Beetz et al. [11].
Intensity and textural PET-IBMs
First, a basic PET-IBM model was created by adding the ‘mean
SUV’ of the parotid gland as an extra variable to the reference
model. Since this variable is the simplest of PET-IBMs, it is the easi-
est to interpret.
Both step-wise forward selection and Lasso regularisation were
performed for multivariable logistic analysis of the PET-IBMs,
together with parotid dose and Xerbaseline. Step-wise forward selec-
tion was based on the largest significant log-likelihood differences
Fig. 1. Example of PET-IBM extraction process. The PET information from the delineated parotid gland was extracted (I). Intensity PET-IBMs were obtained from all voxels
inside this contour (II). The SUVs were binned for the textural analysis (III). For illustration, a Grey Level Run length Matrix is constructed from a binned sample, it quantifies
the number of repetitions of binned SUVs from left to right (IV).
Table 1
Patient characteristics.
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which excludes variables by reducing their coefficients to zero.
The optimal lambda was determined by 100-times repeated
10-fold cross validation [28].
To understand the contribution of the different types of PET-
IBMs to the reference model, the model analysis of all SUV inten-
sity and textural PET-IBMs were conducted separately. Subse-
quently, the resulting SUV intensity and textural models were
compared to the reference and the ‘mean SUV’ model. The perfor-
mance of the constructed models was quantified with the Area
Under the ROC curve (AUC), the Nagelkerke R2 and the discrimina-
tion slope. Furthermore, calibration was evaluated with the
Hosmer–Lemeshow test. Internal validation was performed with
bootstrapping to correct for optimism of the model [29,30]. Analy-
ses were performed with the R-packages ‘Lasso and Elastic-Net
Regularized Generalized Linear Models’ (version 2.0-2) [28] and















No 22 14Inter-variable relationships
The relationship between variables of predictive PET-IBMs
(and Xerbaseline) was investigated with Pearson correlation (con-
tinuous variables) and univariable logistic regression analysis
(binary variables). Furthermore, in a previous study, the short
run emphasis (SRE), which was extracted from CT information
of the parotid gland, was significantly associated with Xer12m
[13]. In the current study, this SRE was also extracted from the
CT-scans of patients without metal artefacts in the images.
Subsequently the correlation of the CT-based SRE values and
the predictive PET-IBMs was tested. Additionally, the improve-
ment of the PET-IBM or reference models by SRE was also tested
in this patient subset.Baseline Xerostomia
No 98 61
A bit 46 29
Quite a bit 13 8
A lot 4 2
Abbreviations: IMRT: intensity-modulated radiation therapy; VMAT: volumetric arc
therapy.Results
Patients
Patient characteristics are depicted in Table 1. Briefly, nearly all
patients were bi-laterally irradiated, most patients had oropharyn-
geal carcinomas and had no baseline xerostomia (none vs. any: 61%
vs. 39%). Sixty of the 161 (37%) patients developed moderate-to-
severe xerostomia (Xer12m).Univariable analysis
In the univariable analysis, the mean dose to the parotid gland
and Xerbaseline were associated with Xer12m. Univariable analysis
Table 2
Estimated coefficients (uncorrected and corrected for optimism) of reference model and PET-IBM models.
b OR (95% CI) p-Value
Uncorrected Corrected
Intercept 2.633 2.579
Xerbaseline 1.559 1.526 4.75 (2.32–9.75) <0.001
PG dose 0.056 0.054 1.06 (1.02–1.10) 0.002
Intercept 0.906 0.828
Xerbaseline 1.473 1.384 4.36 (2.08–9.14) <0.001
PG dose 0.051 0.047 1.05 (1.01–1.09) 0.007
Mean SUV 1.776 1.669 0.17 (0.05–0.64) 0.009
Intercept 1.070 0.984
Xerbaseline 1.487 1.402 4.43 (2.10–9.31) <0.001
PG dose 0.050 0.048 1.05 (1.01–1.09) 0.007
P90 1.620 1.527 0.20 (0.06–0.63) 0.006
Intercept 2.752 2.598
Xerbaseline 1.577 1.479 4.84 (2.29–10.22) <0.001
PG dose 0.055 0.051 1.05 (1.02–1.10) 0.004
LRHG3E 0.938 0.880 0.39 (0.19–0.82) 0.013
Abbreviations: Xerbaseline: xerostomia at baseline; PG dose: contralateral mean dose to parotid gland; P90: 90th percentile of intensities; LRHG3E: Long Run High Grey-level
Emphasis 3; b: regression coefficients; OR: odds ratio; CI: confidence interval.
92 18F-FDG-PET-image biomarkers improve xerostomia predictionshowed that 11 of 24 intensity PET-IBMs and 35 of 66 textural PET-
IBMs were significantly associated with Xer12m (Supplementary
data 3). In general, a negative coefficient was observed for PET-
IBMs that have a positive relationship with SUVs in the parotid
gland, indicating that low parotid gland SUVs were associated with
a high Xer12m risk.Multivariable analysis
Reference model
The reference model with the variables contra-lateral parotid
gland dose and Xerbaseline (none vs. any) was fit to the dataset
(Table 2). The performance measures are depicted in Table 3
(AUC = 0.73 (0.65–0.81), R2 = 0.22).
Intensity PET-IBMs
First, the basic PET-IBM model (‘mean SUV’, parotid dose,
Xerbaseline) showed that the addition of the ‘mean SUV’ significantlyTable 3





Overall 2 log-likelihood 184.51
Nagelkerke R2 0.22
Discrimination Area Under the Curve (AUC) 0.73 (0.65–0.81)
Discrimination slope 0.17
Calibration HL test X2 (p-value) 11.22 (0.19)
Calibration slope (intercept) 1.00 (0.00)
Internal validation AUCcorrected 0.72
Nagelkerke R2corrected 0.20
Abbreviations: HL: Hosmer–Lemeshow; corrected: corrected for optimism with bootstr
tralateral mean dose to parotid gland; P90: 90th percentile of intensities; LRHG3E: Long
NTCP ¼ 1
1 es
where s ¼ 0:984þ 0:048  Contra Dose ðPGÞ þ 1:402  Xerbaseline  1:527improved the reference model (Likelihood ratio test; p = 0.005).
Consistent with the univariable analysis, the negative regression
coefficient of the mean SUV indicates that high mean SUVs were
associated with a lower Xer12m risk (Table 2). The performance of
this basic PET-IBM model (AUC = 0.77 (0.69–0.84), R2 = 0.27), was
better than that of the reference model (Table 3).
Resulting from both the Lasso regularisation and forward selec-
tion, the 90th percentile of SUVs (P90) was the most predictive of
all intensity PET-IBMs (Fig. 2), leading to a significant (Likelihood-
ratio test; p = 0.002), substantial improvement of the model perfor-
mance measures (Tables 2 and 3; AUC = 0.77 (0.70–0.84), R2 = 0.28)
compared to the reference model (AUC = 0.73 (0.64–0.83),
R2 = 0.23). High correlations were observed between P90 and the
IBMs that could also significantly improve the reference model
when individually added to the reference model (q = 0.82 ± 0.15).
See Supplementary data 4 for the correlations of PET-IBMs.
In Fig. 3 the NTCP curves for different P90 values are depicted of
the following P90 model:PET-IBM models
Xerbaseline Xerbaseline Xerbaseline
PG dose PG dose PG dose
mean SUV P90 LRHG3E
176.57 175.30 174.31
0.27 0.28 0.29
0.77 (0.69–0.84) 0.77 (0.70–0.84) 0.77 (0.69–0.84)
0.20 0.21 0.21
4.24 (0.83) 6.72 (0.57) 6.30 (0.61)
0.95 (0.02) 0.95 (0.02) 0.99 (0.00)
0.75 0.76 0.75
0.24 0.25 0.26
apping; IBM: Image Biomarker; Xerbaseline: xerostomia at baseline; PG dose: con-
Run High Grey-level Emphasis 3.
 P90ðPGÞ
Fig. 2. Example of patients with (A) low and (B) high values of mean SUV, P90 and LRHG3E, which were associated with (A) higher and (B) lower risk of developing Xer12m.
Scaling in both images: 0.5–3.5 SUV.
Fig. 3. Normal Tissue Complication Probability (NTCP) values for late xerostomia (Xer12m) of models based on mean SUV (left), P90 (middle) and LRHG3E (right). Curves are
given for the mean PET-IBM values (P90: m = 2.23; LRHG3E: m = 201.24) and for 1 and 2 standard deviation from these mean values (mean SUV: m = 1.93, r = 0.33; P90:
m = 2.23, r = 0.41; LRHG3E: m = 201.24, r = 177.05). For these curves no baseline xerostomia was assumed (Xerbaseline = 0).
L.V. van Dijk et al. / Radiotherapy and Oncology 126 (2018) 89–95 93Textural PET-IBMs
The most predictive textural PET-IBM was the Long Run High
Grey-level Emphasis 3 (LRHG3E), which is derived from theNTCP ¼ 1
1 es
where s ¼ 2:598þ 0:051  Contra Dose ðPGÞ þ 1:479  Xerbaseline  0:880  LRHG3EðPGÞ  201:24177:05GLRLM. The value of this PET-IMB increases when long repetitions
of high SUVs are present in the parotid gland with extra (power of
3) emphasis on high SUVs (see Supplementary data 2 for formula).
This variable was selected by both the Lasso regularisation and the
step-wise forward selection. This variable significantly improved
the reference model in predicting Xer12m (Likelihood-ratio test;
p = 0.001). The negative coefficient of LRHG3E indicated once more
that high SUVs are associated with low Xer12m risk (Table 2). The
addition of LRHG3E improved the reference model performance(0.77 (0.69–0.84), R2 = 0.29; Table 3). The NTCP curves for different
LRHG3E are depicted in Fig. 3 for the following model:Inter-variable relationships
The predictive PET-IBM P90 (intensity) and LRHG3E (textural)
were closely correlated (p < 0.001; r = 0.83). Moreover, they did
not add independent information to each other in predicting
Xer12m (Likelihood ratio test; p > 0.21). Univariable logistic analysis
showed no significant association between Xerbaseline and P90
(p = 0.079) or LRHG3E (p = 0.465).
In the current study cohort, 100 patients did not have metal
artefacts in the CT images and could therefore be used for the anal-
94 18F-FDG-PET-image biomarkers improve xerostomia predictionysis of the CT-based IBM, the short run emphasis (SRE) [13]. This
CT-based SRE was significantly correlated to the predictive PET-
IBM P90 (p = 0.008; r = 0.26) and LRHG3E (p = 0.026; r = 0.22).
The SRE neither significantly improved the reference model (likeli-
hood ratio test, p = 0.055), nor did it add to the PET-IBM models
with P90 (likelihood ratio test, p = 0.140) and LRHG3E (likelihood
ratio test, p = 0.096) in this cohort subset.
Discussion
This study is novel to show that the high metabolic activity of
the parotid gland was associated with a lower risk of developing
late xerostomia (Xer12m). Moreover, the prediction of late xerosto-
mia was significantly and substantially improved with addition of
patient-specific PET-IBMs to the reference model based on dose
and Xerbaseline. These findings could improve understanding of nor-
mal tissue response following radiotherapy, since the variation in
patient-specific PET characteristics can partly explain the unex-
plained variance in predicting xerostomia with dose parameters.
Moreover, it could improve identification of patients that are at
risk of late radiation-induced side effects, which could potentially
benefit most from new therapy technology such as proton [7]
and MRI-guided irradiation [8]. In other words, better prediction
of toxicities could improve the treatment decision support [9,32].
However, external validation of the PET-IBM models in an
independent dataset is necessary before clinical implementation
[33].
The PET-IBM that indicates the minimum value of the 90% high-
est SUVs (P90) was the most predictive of all intensity PET-IBMs.
The mean SUV also performed well, but P90 appeared more rele-
vant in this dataset. A high P90 was associated with a lower risk
of developing late xerostomia. Similar effect and predictive
improvement was observed from LRHG3E (Long Run High Grey-
level Emphasis 3) of the textural PET-IBMs, which significantly cor-
related with P90 (q = 0.83). This PET-IBM indicates high SUVs that
are spatially adjacent to each other. Both PET-IBMs were negatively
associated with Xer12m, suggesting that patients with low meta-
bolic activity in the parotid glands were at risk of developing late
xerostomia. Although both P90 and LRHG3E perform similarly, cur-
rently the P90 is simpler to calculate. However, LRHG3E also con-
tains information about the spatial connectivity of the high SUV
voxels, i.e. large repetitions of voxels with high SUV increase the
LRHG3E values. External validation is needed to confirm the pre-
dictive power of LRHG3E over P90. Additionally, an alternative
variable selection approach, Lasso regularisation, resulted in very
comparable final models. Since they were independent of the
method of analysis, it suggests that the associations in this dataset
were relatively stable.
Predictive PET-IBMs were not significantly associated with
Xerbaseline. This suggests that PET-IBMs contain unique and addi-
tional information to baseline xerostomia complaints, since the
addition of PET-IBMs to Xerbaseline (and PG dose) improved the pre-
diction of Xer12m significantly.
This study suggests that high metabolic parotid glands have
more viable cells (parenchyma and/or stem cells) with more repair
capability and/or are less radiosensitive. Although possibly driven
by multiple underlying biological processes, there is some similar-
ity in the tumour reaction to radiation. For tumour tissue it is
known that high metabolic tumours are more likely to recur [34],
particularly in their high metabolic regions [35]. A possible expla-
nation is that it arises from a combination of higher cell density,
proliferation rate of metabolically active tissue and DNA repair
capacity [36].
Other studies have shown that parotid gland SUVs decrease
post-radiotherapy, and in addition that this change was associated
with parotid gland dose [37,38]. Cannon et al. [38] showed thatmean ‘SUV-weighted parotid gland dose (voxel-wise)’ was
significantly related to fractional-SUV (post-SUV/pre-SUV). In an
additional small cohort (n = 8), they showed that fractional-SUV
was significantly associated with fractional salivary flow and
physician-rated xerostomia. Although this indirectly suggests that
‘SUV-weighted parotid gland dose’ is related to xerostomia mea-
sures, the direct and separate associations of parotid gland dose
and pre-treatment SUV with xerostomia measures or fractional
SUV were unfortunately not described.
In previous work, a positive association was shown between
higher risk of developing late xerostomia and CT-based SRE (Short
Run Emphasis), which might be related to the ratio between non-
functional fatty tissue and functional parotid parenchyma tissue. In
this study, we showed that this CT-IBMwas significantly correlated
to P90 and LRGH3E in patients without metal artefacts (n = 100)
and did not significantly add to the PET-IBM models. Additionally,
the performance of predicting Xer12m was substantially higher
with PET-based IBM models than with than CT-based IBMs. This
suggests that 18F-FDG PET is better to quantify the ratio between
fatty non-functional and functional parotid parenchyma tissue.
This is logical since 18F-FDG PET is a functional image modality.
Furthermore, the SRE did not show a significant improvement in
the reference model for the cohort subset, which might be caused
by the small additive effect of SRE and low number of patients on
which this IBM could be tested.
A well-defined protocol was used to ensure optimal standardi-
sation of SUV in the 18F-FDG PET images by correcting for body-
weight, injection dose, tracer uptake period, and glucose plasma
levels by letting the patients fast [19,20]. Although SUVs may also
be affected by fasting blood glucose level, muscle activity, liver and
kidney function, the images were not corrected for these fluctua-
tions. Furthermore, patients with metal artefacts in CT images
were included, where the attenuation correction can influence
SUVs, but this bias will primarily be located around the metal
implant [20]. Additional analyses showed that the PET-IBMs’ per-
formance was still good in the sub cohort of patients without metal
artefacts. Additionally, future improvements of the consistency
and spatial resolution of PET imaging should also improve the per-
formance of the PET-IBMs in predicting Xer12m.
In this study, patient-rated outcomes (EORTC QLQ-H&N35
questionnaire) were used as a measure for moderate-to-severe
xerostomia, because of their relationship with the quality of life
of HNC patients [10]. However, some unexplained variability of
the models may be caused by the assessment of xerostomia, as
the questionnaires can be interpreted differently by the individual
patients [39]. Our current study could be strengthened by the addi-
tion of investigating the associations between PET-IBMs and objec-
tive xerostomia measures. Parotid flow rates are often used, but
several studies have shown no or modest correlation between
patient reported xerostomia and parotid flow rates [40] and have
a low reproducibility [41]. Another example is scintigraphy of par-
otid gland ejection fraction over time. Although this technique
seems promising as a quantitative measure for xerostomia, it
requires additional scans with complex procedures with radioac-
tive tracers [41]. This highlights the importance for future research
on a non-invasive, accessible and reliable quantitative measure of
xerostomia. Nevertheless, we believe that patient-rated xerosto-
mia remains an important endpoint, due to its clinical importance
and practical benefits.
Conclusion
The pre-treatment PET-IBMs indicated that a large quantity
of high SUVs in the parotid gland was significantly associated
with a lower risk of developing xerostomia 12 months after
radiotherapy. The addition of the predictive intensity PET-IBM
L.V. van Dijk et al. / Radiotherapy and Oncology 126 (2018) 89–95 95(90th percentile of SUV) to a model with parotid gland dose and
baseline xerostomia improved the prediction performance of the
reference model substantially (from 0.73 (0.65–0.81) to 0.77
(0.70–0.84)). This study highlights the importance of
incorporating patient-specific functional characteristics into
NTCP model development and can, thereby, contribute to the
understanding of the patient-specific response of healthy tissue
to radiation dose.
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